Clinical TrialsSearch results for "cytarabine"
Number of results: 247
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18
Completed
- First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Acute lymphocytic leukemia Acute myeloid leukemia refractory Myelodysplastic syndromes BPDCN
- Obara Kentaro
- 2024-11-18